X4 Pharmaceuticals, Inc. (XFOR)
NCM · Healthcare · Biotechnology
Closing price as of 2026-06-08 · Source: TEK2day Finance
Key Metrics
About X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 2.0M | 1.8M | 2.6M | 2.7M |
| Gross Profit | 1.6M | 1.4M | 2.2M | 2.1M |
| Operating Income | -26.2M | -27.5M | -23.7M | -20.3M |
| Net Income | -25.7M | -29.8M | -23.9M | -20.2M |
| Diluted EPS | $-3.47 | $-0.69 | $nan | $-0.16 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 2.6M | 35.1M |
| Gross Profit | 0.00 | 0.00 | 1.8M | 29.4M |
| Operating Income | -88.1M | -107.5M | -141.4M | -86.9M |
| Net Income | -93.9M | -101.2M | -37.5M | -79.2M |
| Diluted EPS | $-45.60 | $-17.07 | $-5.70 | $-1.87 |